NRAS

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
木曜日, 5月 9, 2024
Diamond, FDA, Cancer, Foundation Medicine, Mutation, Investment, HGG, Food, Research, Lung cancer, GBM, Development, Administration, ASCO, TKI, Helmy Eltoukhy, BRAF, Patient, Society, G&A, AACR, Annual general meeting, Prevalence, NRAS, Pharmaceutical industry

Cash Position: Black Diamond ended the first quarter of 2024 with approximately $115.2 million in cash, cash equivalents, and investments compared to $131.4 million as of December 31, 2023.

Key Points: 
  • Cash Position: Black Diamond ended the first quarter of 2024 with approximately $115.2 million in cash, cash equivalents, and investments compared to $131.4 million as of December 31, 2023.
  • Net cash used in operations was $21.2 million for the first quarter of 2024 compared to $20.0 million for the first quarter of 2023.
  • Net Loss: Net loss for the first quarter of 2024 was $18.2 million, as compared to $20.9 million for the same period in 2023.
  • Black Diamond ended the first quarter of 2024 with approximately $115.2 million in cash, cash equivalents and investments which the Company believes is sufficient to fund its anticipated operating expenses and capital expenditure requirements into the third quarter of 2025.

Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress

Retrieved on: 
水曜日, 5月 8, 2024
Mutation, Safety, Pembrolizumab, Research, Asian literature, CRC, RAS, SHP2, Initiation, Trial of the century, Disclosure, PDAC, BRAF, Patient, SOC, Neoplasm, NRAS, AACR, Clinical trial, Sanofi, G13, GAAP, Lung cancer, Pharmaceutical industry

REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2024, and provided an update on corporate progress.

Key Points: 
  • REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2024, and provided an update on corporate progress.
  • The company continues making progress on its 2024 development priorities:
    Advancing its RAS(ON) multi-selective inhibitor RMC-6236 into monotherapy pivotal trials.
  • Revenue: Total revenue was zero for the quarter ended March 31, 2024, compared to $7.0 million for the quarter ended March 31, 2023.
  • Revolution Medicines will host a webcast this afternoon, May 8, 2024, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

Erasca Reports First Quarter 2024 Business Updates and Financial Results

Retrieved on: 
水曜日, 5月 8, 2024
Research and development, Research, Survival, Conference, Administration, MEK, Novartis, Data, Patient, Melanoma, SAN, NRAS, Pharmaceutical industry

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended March 31, 2024.

Key Points: 
  • SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended March 31, 2024.
  • Research and Development (R&D) Expenses: R&D expenses were $28.6 million for the quarter ended March 31, 2024, compared to $27.6 million for the quarter ended March 31, 2023.
  • General and Administrative (G&A) Expenses: G&A expenses were $10.3 million for the quarter ended March 31, 2024, compared to $9.4 million for the quarter ended March 31, 2023.
  • Net Loss: Net loss was $35.0 million, or $(0.23) per basic and diluted share, for the quarter ended March 31, 2024, compared to $33.2 million, or $(0.22) per basic and diluted share, for the quarter ended March 31, 2023.

Immuneering Recognizes Melanoma Awareness Month

Retrieved on: 
月曜日, 5月 6, 2024
Cancer, Mutation, Lung cancer, Safety, Pharmacokinetics, Pancreatic cancer, Binimetinib, RAS, Research, Half-life, Skin cancer, Melanoma, Cycle, BRAF, Patient, Benchmarking, HRAS, MAPK, Physician, Neoplasm, AACR, RAF, Biomarker, PD, NSCLC, Growth, NRAS, Medical imaging

CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, recognizes the importance of early detection and treatment during Melanoma Awareness Month, and highlights RAS mutant melanoma as the focus of one of the five arms in its ongoing Phase 2a clinical study for its lead program IMM-1-104. RAF or RAS mutant melanoma is also being evaluated in its Phase 1/2a clinical study of IMM-6-415 in patients with advanced solid tumors.

Key Points: 
  • CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, recognizes the importance of early detection and treatment during Melanoma Awareness Month, and highlights RAS mutant melanoma as the focus of one of the five arms in its ongoing Phase 2a clinical study for its lead program IMM-1-104.
  • RAF or RAS mutant melanoma is also being evaluated in its Phase 1/2a clinical study of IMM-6-415 in patients with advanced solid tumors.
  • Melanoma Awareness Month is held each May to raise awareness, galvanize advocates and support research efforts toward new treatments and methods of detecting melanoma, the most serious type of skin cancer.
  • “Several biomarkers are known to drive the growth and progression of melanoma and there are therapies being clinically evaluated with the potential to target these tumor biomarkers.”
    “Immuneering is proud to acknowledge Melanoma Awareness Month, especially since melanoma is a key area of focus in our development of IMM-1-104 and mutations in the RAS gene family are known to be present in approximately 20-25% of all melanomas,” said Brett Hall, Ph.D., Chief Scientific Officer, Immuneering Corporation.

Erasca Announces $45 Million Oversubscribed Private Placement Financing

Retrieved on: 
木曜日, 3月 28, 2024
BofA Securities, Survival, Patient, SAN, Research, Sale, Prospectus, NRAS

Erasca anticipates the gross proceeds from the private placement will be approximately $45 million, before deducting placement agent fees and other offering expenses.

Key Points: 
  • Erasca anticipates the gross proceeds from the private placement will be approximately $45 million, before deducting placement agent fees and other offering expenses.
  • The private placement is expected to close on or about April 2, 2024, subject to customary closing conditions.
  • The private placement was led by a high quality group of new and existing healthcare focused investors.
  • BofA Securities is acting as sole placement agent to Erasca in connection with the private placement.

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

Retrieved on: 
水曜日, 3月 27, 2024
Administration, EGFR, Mutation, Index, Colorectal cancer, Cetuximab, Central nervous system, Novartis, Webcast, Patient, GBM, CNS, Neoplasm, Acquisition, G&A, Insurance, BRAF, NRAS, MEK, CRC, Melanoma, ASCO, ID, MTD, Research and development, Probability, Data, FDA, Outsourcing, FTD, Pharmaceutical industry

SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter and full year ended December 31, 2023.

Key Points: 
  • In addition, a strategic pipeline prioritization sharpened Erasca’s focus on existing programs that we believe have the highest probability of success for patients.
  • Research and Development (R&D) Expenses: R&D expenses were $24.8 million for the quarter ended December 31, 2023, compared to $29.4 million for the quarter ended December 31, 2022.
  • General and Administrative (G&A) Expenses: G&A expenses were $9.1 million for the quarter ended December 31, 2023, compared to $8.7 million for the quarter ended December 31, 2022.
  • Erasca will hold a conference call and webcast on Thursday, March 28, 2024 at 8:30 am ET.

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Retrieved on: 
水曜日, 3月 27, 2024
Mutation, RAF, MAPK, Growth, Half-life, PD, Colorectal cancer, RAS, Patient, Neoplasm, Cancer, HRAS, DCI, Human, Binimetinib, AACR, NRAS, Safety, Cycle, Pharmacokinetics, Encorafenib, Pharmaceutical industry

CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the first patient has been dosed in its Phase 1/2a trial of IMM-6-415 to treat advanced solid tumors with RAF or RAS mutations.

Key Points: 
  • In animal studies, IMM-6-415 strongly inhibited the growth of tumors with RAF or RAS mutations, as both a monotherapy and in combinations.
  • “We are pleased to have dosed the first patient in our Phase 1/2a trial for IMM-6-415, our second product candidate to enter the clinic,” said Ben Zeskind, Chief Executive Officer, Immuneering Corporation.
  • We believe the shorter half-life of IMM-6-415 could provide a potential treatment option for a broad patient population with RAS or RAF mutations.
  • The trial will include solid tumor patients with any mutation in RAF, KRAS, NRAS, or HRAS who meet the enrollment criteria.

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
火曜日, 3月 12, 2024
Diamond, Research, Administration, EGFR, Mutation, RAF, Development, HGG, Patient, GBM, Neoplasm, Cancer, Lung cancer, BRAF, AACR, Treatment, Investment, NRAS, Clinical trial, Therapy, Poster, FDA, Food, Pharmaceutical industry

The presentation included clinical data from 27 patients with advanced/metastatic NSCLC who received once daily doses ranging from 25mg to 400mg.

Key Points: 
  • The presentation included clinical data from 27 patients with advanced/metastatic NSCLC who received once daily doses ranging from 25mg to 400mg.
  • The trial is currently in dose escalation with an update anticipated in the fourth quarter of 2024.
  • (NCT05786924)
    Cash Position: Black Diamond ended 2023 with approximately $131.4 million in cash, cash equivalents, and investments compared to $122.8 million as of December 31, 2022.
  • Net Loss: Net loss for the fourth quarter of 2023 was $19.4 million, as compared to $21.1 million for the same period in 2022.

i3Forum Announces Launch of One Consortium to Restore Trust in International Communications

Retrieved on: 
金曜日, 3月 15, 2024
Security, Data Management, Other Communications, Technology, Public Relations, Investor Relations, Audio, Video, Marketing, Advertising, Communications, Other Technology, Telecommunications, Software, Networks, VoIP, Internet, Mobile, Wireless, NRAS, Organization, GSC, Communication, Trust, ATIS, Foot, GLF, Policy, BICS, Life, Consortium, Ecosystem, Multimedia, Hello, Restore Trust, GSMA, Human

The loss of public trust in communications is driven by the proliferation of unwanted/illegal voice calls and messages (e.g.

Key Points: 
  • The loss of public trust in communications is driven by the proliferation of unwanted/illegal voice calls and messages (e.g.
  • Philippe Millet, Founder and Chairman of the i3Forum, commented: "This is the first tangible milestone for The Restore Trust initiative.
  • Rebekah Johnson, founder and CEO, Numeracle added, "Numeracle's mission from day one has been to restore trust to communications.
  • The i3Forum One Consortium initiative is a promise: to foster collaboration and earnest communication among industry, associations, and regulators to combat fraud and restore that trust.

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories

Retrieved on: 
金曜日, 3月 1, 2024
NRAS, BRAF, Acquisition, SAN, KNTE, APA, SAS, Sale, Contingent value rights, RAS, RAF, Patient, Tax, Health care, Development, MEK, Lazard, Melanoma, Pharmaceutical industry

Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.

Key Points: 
  • Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.
  • SAN FRANCISCO, SAN DIEGO and CASTRES, France, March 01, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc .
  • (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, and Pierre Fabre Médicament, SAS (“Pierre Fabre Laboratories”), a global player in oncology, today announced their agreement to the sale of the Company’s investigational pan-RAF inhibitor, exarafenib, and other pan-RAF program assets pursuant to the APA entered into by the parties.
  • In addition, Pierre Fabre Laboratories will assume up to $5 million of trade payables for the transferred assets.